VPS34 inhibitor (Global Cancer Technology/Barrow Neurological Insitute/Neuropore Therapies)

N/A

Report date: 2025/01/26 16:03:34
NME

Base Information

Drug NameVPS34 inhibitor (Global Cancer Technology/Barrow Neurological Insitute/Neuropore Therapies)
Drug Alias NameVPS34 inhibitor (Neuropore Therapies/Global Cancer Technology)Autophagy modulator (Neuropore Therapies/Global Cancer Technology)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3-kinase catalytic subunit type 3 inhibitors
TargetsPhosphatidylinositol 3-kinase catalytic subunit type 3
Therapy Area/IndicationsNerve DegenerationGlioblastomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNeuropore Therapies Inc
China Registration ClassN/A

Develop Information

Active CompaniesBarrow Neurological InsituteGlobal Cancer TechnologyNeuropore Therapies Inc
Inactive CompaniesN/A
Active IndicationsNerve DegenerationGlioblastoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A